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Abstract
The human immature K562 erythroid cell line was studied for its capacity to produce and to metabolize the phospholipid
 .molecule platelet-activating factor PAF . K562 cells produced PAF under calcium ionophore stimulation. Lyso PAF and
 .acetyl-CoA the acetate donor molecule for the acetylation of lyso PAF into PAF had no effect on the amounts of PAF
produced by ionophore-stimulated cells. The metabolism of PAF and lyso PAF by K562 cells was compared to that of
w3 xfreshly-isolated human bone marrow erythroblasts and blood erythrocytes. K562 cells rapidly metabolized H PAF and
w3 xH lyso PAF with 1-alkyl analogue of phosphatidylcholine as the major metabolic product. In contrast, blood erythrocytes
did not. PAF acetylhydrolase activity levels in K562 cells and bone marrow erythroblasts were similar and higher than in
 . w3 xblood erythrocytes. PAF 1–100 nM stimulated H thymidine incorporation in K562 cells grown in low serum concentra-
tion, a non-metabolizable PAF agonist being more potent than PAF to stimulate thymidine incorporation. PAF receptor
mRNA was detected in K562 cells by polymerase chain reaction on reverse transcripts. The present study demonstrates that
K562 cells produce and metabolize PAF and underlines the putative role of erythroid precursors in the modulation of bone
marrow PAF concentrations. The effect of PAF on the growth of K562 cells might be mediated through PAF receptors
suggesting a potential role of PAF on the proliferation and functions of human erythroid marrow precursors. q 1997
Elsevier Science B.V.
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1. Introduction
 .Platelet-activating factor PAF is a phospholipid
compound produced by most inflammatory stimu-
w xlated cells 1,2 . PAF derives from the membrane
precursor 1-alkyl-2-acyl-glycero-3-phosphocholine.
) Corresponding author. Fax: 33 5 5543 5801.
The action of a phospholipase A -dependent process2
generates the lyso PAF, and the subsequent acetyla-
tion of the lyso compound in the presence of acetyl-
w xCoA by an acetyltransferase generates PAF 3 . PAF
levels are regulated by an acetylhydrolase activity
 .AHA which cleaves the acetyl group from the sn-2
position to convert PAF into lyso PAF which is then
reacylated into membrane phospholipids by an acyl-
 . w xtransferase activity ATA 3,4 .
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w xBlood erythrocytes do not produce PAF 5 but
w x w xcontain AHA 5 and ATA 6 . Both AHA and ATA
are gradually reduced during in vivo aging of
w xerythrocytes 6 . Cell maturation and differentiation
change the processes of PAF production and degrada-
tion as well as the responsiveness of cells to PAF
w x7–9 . In this study, we have compared AHA level,
and the metabolism of PAF and lyso PAF in the
immature erythroid K562 cell line, in freshly-isolated
human bone marrow erythroblasts and in blood ery-
throcytes. We have also investigated the capacity of
K562 cells to produce PAF, the presence of PAF
receptors on K562 cells, and the effect of PAF on
their growth.
2. Materials and methods
2.1. Reagents
Synthetic C –PAF Sigma, Saint Quentin16
.Fallavier, France , the non-metabolizable PAF ago-
nist 1-O-hexadecyl-2-N-methylcarbamyl-sn-glycero-
 . 3-phosphocholine C–PAF , Novabiochem, Switzer-
.  .land , synthetic lyso C –PAF Sigma , and the PAF16
receptor antagonist CV 3988 and BN 52021 Tebu,
.Le Perray en Yvelines, France were dissolved
 .10 mM in 60% ethanol, stored at y208C, and ap-
propriately diluted in 2% human serum albumin
 .  .HSA from Bio Merieux France before use. Cal-
 .cium ionophore A23187 Sigma was dissolved
 .10 mM in DMSO, stored at y208C, and appropri-
ately diluted in RPMI 1640 immediately before use.
 .  .Phosphatidylcholine PC , neutral lipid NL , bovine
 . 2q 2qserum albumin BSA , mepacrine, Ca , Mg ,
 . XEDTA, phenylmethylsulfonyl fluoride PMSF , 5,5 -
 .  .dithiobis 2-nitro-benzoic acid DTNB , p-
 .bromophenacyl-bromide p-BPB , creatine phospho-
kinase and creatine phosphate were from Sigma.
 .Hanks’ balanced salts solution HBSS , RPMI 1640,
 .penicillin, streptomycin and fetal calf serum FCS
 .were from Gibco Cergy Pontoise, France . Aspirin
 . lysin salt Aspegic was from lab Egic Amilly,
. w3 x w3 xFrance . H -thymidine and the mixture of H al-
w x kyl– C and C –PAF were from Amersham Les16 18
. w3 x Ulis, France . H acetyl–PAF was from NEN Les
.Ulis, France .
2.2. Proliferation studies
K562 cells were obtained from the American Type
 .Culture Collection Rockville, MD . Cells were grown
in suspension in RPMI 1640 supplemented with 10%
 .FCS, penicillin 100 Urml and streptomycin
 .100 mgrml at 378C in 5% CO in air. Before use,2
cells were washed twice in HBSS and numerated.
 4 .Cells 1=10 per well were cultured in 96-well
microtiter plates in 100 ml of RPMI with low FCS
 .concentrations 1% or 5% in the presence of PAF,
C–PAF, CV 3988 and BN 52021 both from 10 mM
. to 0.1 nM or the appropriate vehicle 10 ml 2%
.HSA . After 64 h of incubation, cultures were pulsed
w3 xfor 8 h with 1 mCirml H thymidine and cells were
harvested using a Skatron cell harvester. Each experi-
ment was carried out as sixplicates. Percent of varia-
tion of dpm incorporation was calculated as follows:
wmean experimental dpm y mean control
. xdpm rmean control dpm =100. Data were com-
pared using the student’s t-test for paired variables.
2.3. Isolation of human marrow erythroblasts and
blood erythrocytes
Human bone marrow erythroblasts were isolated
from bone marrow samples collected by aspiration
into heparinized tubes Vacutainer system, Becton
.Dickinson, Meylan, France . The procedure was per-
formed according to the Helsinki recommendations.
Mononuclear marrow cells were isolated by separa-
 .tion on a Ficoll gradient 400=g, 20 min and washed
 .twice with HBSS 400=g, 10 min . They were incu-
bated for 15 min at 48C with IgG monoclonal anti-3
bodies clone NaM10-2H12, Bioatlantic, Nantes,
.France against glycophorin A. After washing, the
cells were incubated with immunomagnetic beads
covalently coupled with sheep antimouse IgG Dynal,
.Compiegne, France according to the manufacturer’s`
recommendations. Cells binding the antibody-coated
beads were then removed using a magnet and washed.
Mononuclear cells obtained after selection consisted
of 98"1% of bone marrow erythroblasts mean"
.SEM of four experiments with more than 97% of
mature erythroblasts polychromatic and orthochro-
.matic and less than 3% of immature erythroblasts
 .pro-erythroblasts and basophilic erythroblasts .
( )F. Dupuis et al.rBiochimica et Biophysica Acta 1359 1997 241–249 243
For preparation of erythrocytes, human blood was
drawn from healthy volunteers using heparin as anti-
coagulant. The buffy coat was aspirated and dis-
carded. The red cells were washed three times with
HBSS before used.
2.4. Formation and release of PAF by K562 cells
Cells were washed twice with HBSS to eliminate
 6.FCS before used. Cells 5=10 were assessed for
PAF contents before and after stimulation with cal-
 .cium ionophore A23187 2 mM for 10 min. The
released and the cell-associated PAF were ethanol-ex-
tracted from supernatants and cells by mixing super-
natants with 4 ml ethanol and cell pellets with 2 ml of
w x80% ethanol for 5 h at room temperature 10 . After
 .centrifugation 1500=g, 20 min , the ethanolic su-
pernatants were dried, recovered in 100 ml of 60%
ethanol and stored at y208C until assayed.
2.5. PAF assay and characterization
PAF activity was measured by platelet aggregation
of washed rabbit platelets as previously described
w x11 . Aspirin-treated washed rabbit platelets were
stirred in 300 ml Tyrode buffer containing 0.25%
gelatin, 1 mM creatine phosphate, and 10 Urml crea-
 .tine phosphokinase pH 7.4 . Aggregating activity of
the samples was measured using a calibration curve
obtained with 2.5–20 pg of synthetic C –PAF. Re-18
 .sults were expressed in picograms pg of PAF per
5=106 cells as mean of duplicate samples.
In addition to its ADP- and arachidonic acid-inde-
pendent aggregating activity on rabbit platelets, the
lipidic material obtained from cells was further char-
acterized as PAF on the basis of the following crite-
 .ria: 1 study of the aggregating activity in the pres-
ence of 0.1 mM BN 52021 or CV 3988, two specific
w x  .PAF receptor antagonists 12 ; and 2 retention time
 . w xduring thin-layer chromatography TLC analysis 13 .
Briefly, samples of cell-derived PAF were mixed
together and evaporated. The dry residues were re-
covered in 150 ml of chloroformrmethanol 1r1,
. vrv and analyzed using TLC plates Silica gel 60
 . .20=20 cm, 0.5 mm , Merck, France , eluted with
 .chloroformrmethanolrwater 70r35r5, vrv .
w3 xH PAF was used as standard. Areas of samples on
TLC plates with RF values corresponding to the PAF
standard were extracted, suspended in 60% ethanol,
and assayed for PAF activity as described before.
2.6. Assay of lyso PAF
 6.Cells 5=10 were washed twice with HBSS to
eliminate FCS before use. Lyso PAF was measured
in ethanolic extracts of cell pellets after its chemical
w xacetylation into PAF as previously described 10 .
Briefly, ethanolic samples were dried, then mixed
with 200 ml of pyridine and 200 ml of acetic anhy-
dride and kept overnight, in the dark, at room temper-
ature. After evaporation of the reagents and removing
of the traces of pyridine by chloroform, the dried
samples were recovered with 100 ml of 60% ethanol,
and PAF was bioassayed as described before. Results
were expressed in nanograms of lyso PAF per 5=106
cells.
[3 ] [3 ]2.7. H PAF and H lyso PAF metabolism by
K562 cells, freshly-isolated bone marrow -
erythroblasts and blood erythrocytes
 6.K562 cells 5=10 , bone marrow erythroblasts
 6. 2.5=10 and peripheral blood erythrocytes 5=
8.10 were incubated at 378C in a volume of 1 ml of
RPMI 1640 for various periods of time in the pres-
w3 x w xence of a mixture of H alkyl– C and C –PAF16 18
w3 x w x or H alkyl– C –lyso PAF final concentration16
. 0.05 nmolrtube; 0.5 mCi complexed to HSA final
.concentration 2 mgrml . Experiments were per-
formed in duplicate. The PAF metabolism was as-
sessed after extraction of lipids from cells or super-
w xnatants 14 . Recovery of added radioactivity after
lipid extraction was 85%. The labeled compounds
w3 x w3 xderived from H alkyl–PAF and H alkyl–lyso PAF
 were separated using TLC plates Silica Gel 60 20
..= 20 cm, 0.25 mm eluted with chloroformr
 . w xmethanolracetic acidrwater 50:25:8:4, vrv 13 .
Each lane was divided in areas of 0.5 cm length,
which were scraped into vials and radioactivity was
measured on a Packard liquid scintillation counter.
Labeled PAF and lyso PAF and unlabeled PC and
NL were used as standards.
In a separate set of experiments, incubation of
w3 xH alkyl–PAF with K562 cells was performed in the
presence of 10 mM Ca2q, 10 mM Mg2q, 10 mM
EDTA, 0.5 mM PMSF, 0.5 mM mepacrine, 0.5 mM
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DTNB, 0.01 mM p-BPB various molecules known
w x.to affect PAF metabolism 3,4 , 10 mM BN 52021
and 10 mM CV 3988. In these experiments, the la-
beled products recovered include both cell-associated
components and those present in the medium. After
lipids extraction, the labeled compounds derived from
w3 xH alkyl–PAF were separated using TLC plates as
described above.
2.8. Assay for AHA
 6.AHA was assessed on K562 cells 1=10 , hu-
 6.man bone marrow erythroblasts 1=10 , and blood
 8.erythrocytes 1=10 . Cells were stored at y808C
until AHA assayed. AHA was assessed as previously
w x 5 w3 xreported 13,15 . Briefly, 10 dpm of H acetyl–
 .C –PAF 10 Cirmmol, NEN , 0.1 mM C –PAF,16 16
AHA buffer NaCl, 140 mM; KCl, 3 mM; HEPES,
.  .4 mM; EDTA, 22 mM pH 8 in a final volume of
450 ml, and 50 ml cell extracts were incubated for
20 min at 378C. The reaction was stopped with 100 ml
 .  .BSA 10% and 400 ml trichloroacetic acid 20% .
 .Samples were centrifuged 1500=g, 15 min and
supernatants were counted in a liquid scintillation
counter. AHA was also assessed in RPMI 1640 with
 .or without FCS 1–20% . Results were expressed as
picomoles PAF degraded per min per 1=106 cells as
means of duplicate determinations. The variation be-
tween duplicates was less than 5%.
2.9. Assessment of PAF receptor mRNA from K562
cells
Experiments of reverse transcriptase polymerase
 .chain reaction RT–PCR were performed as previ-
w xously described 16 . Briefly, total RNA was ex-
 6.tracted from K562 cells 20=10 , using Triazol-
 .Reagent Gibco according to the manufacturer’s pro-
cedure. First Strand cDNA was synthesized from
5 mg of total RNA according to the procedure of
Pharmacia Biotech using murine reverse transcriptase
and the First Strand cDNA synthesis kit. Oligonu-
cleotides based on the published sequences for
.guinea-pig and human PAF receptor cDNA were
 .synthesized by Genosis UK . The following primer
pairs were used to amplify PAF receptor cDNA:
 X.  X.  .5 GTGCTCGGGGTCATTGCTAATG 3 sense
 X.  X. and 5 AAATTCCTGTGCAACGTGGC 3 anti-
.  .sense . Ten ml 1r5 of the PCR samples were
loaded onto ethidium bromide stained agarose gel
and visualized under UV illumination. PCR product
was obtained by RT–PCR from total RNA and its
identity to PAF receptor was also confirmed by cDNA
sequencing carried out by ESGS Euro Sequences´
.Genes Services, Montigny, France .`
3. Results
3.1. AHA in FCS, K562 cells, bone marrow-
erythroblasts and blood erythrocytes
No AHA was detected in RPMI 1640 alone. The
mean AHA levels detected in medium with 1, 5, 10
w3 x  .Fig. 1. Time-course of the conversion of H alkyl–PAF v to
w3 x  . w3 x  . w3 xH alkyl–lyso PAF I , H alkyl–PC ‘ , and H alkyl–neu-
 .  6.tral lipids l by K562 cells. Cells 5=10 were washed twice
to eliminate serum and were incubated at 378C in 1 ml of RPMI
1640 with labeled PAF. After various time of incubation, lipids
in cells and supernatants were extracted and labeled compounds
separated using TLC plates. Results are expressed as the percent-
 .  .age of total radioactivity in dpm recovered in cells upper and
 .supernatants lower . The values are means"SEM of three ex-
periments in duplicate.
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 .  .Fig. 2. Effects of CV 3988 10 mM and BN 52021 10 mM on
w3 x w3 x w3 xthe conversion of H alkyl–PAF to H alkyl–lyso PAF, H al-
w3 xkyl analogue of PC, and H alkyl–neutral lipids in K562 cells.
Results are expressed as the percentage of total radioactivity in
.dpm recovered following incubation of labeled PAF with K562
cells for 30min. The values are mean"SEM of three experi-
) ments in duplicate. P -0.05 as compared with control Mann-
.Whitney U-test .
and 20% FCS were 78, 376, 661 and
 .1159 pmolrminrml, respectively four experiments .
The mean AHA levels detected in K562 cells,
freshly-isolated bone marrow erythroblasts and blood
erythrocytes were 250, 210 and 0.17 pmolrminr1=
6 10 cells, respectively Mean"SEM of three inde-
.pendent experiments in duplicate .
3.2. Metabolism of PAF and lyso PAF by K562 cells,
bone marrow erythroblasts and blood erythrocytes
After 10, 30, 60 and 300 min of incubation with
w3 xH alkyl–PAF, K562 cells had incorporated 54, 80,
85 and 91% of the initially added radioactivity, re-
 .spectively ns3 . The distribution of label in K562
cells and culture medium is shown in Fig. 1. The
w3 xtime-dependent decrease in H alkyl–PAF amount
paralleled with the time-dependent increase in 1-
w3 x H alkyl analogue of PC amount i.e., with a long
chain acyl group at the sn-2 position of the glycerol
.backbone . At each point of time, less than 5% of the
radioactivity in cells migrated with lyso PAF. No
w3 xsignificant difference was found when the H alkyl–
PAF catabolism was assessed in the presence of Ca2q
 . 2q  .  .10 mM , Mg 10 mM , EDTA 10 mM , DTNB
 .  .  .0.5 mM , mepacrine 0.5 mM , PMSF 0.5 mM and
 .  .p-BPB 0.01 mM data not shown . The metabolism
of PAF in 1-alkyl–2-acyl analogue of PC by K562
cells decreased in the presence of the PAF receptor
 .antagonist CV 3988 10 mM while BN 52021
 .  .10 mM had no effect Fig. 2 .
After 10, 30, 60 and 300 min of incubation with
w3 xH alkyl–lyso PAF, K562 cells had incorporated 77,
88, 92 and 94% of the initially added radioactivity,
respectively. The distribution of label in cells and
culture medium as a function of time is shown in Fig.
3. Lyso PAF was quickly reacylated in K562 cells
into 1-alkyl-analogue of PC.
w3 xFig. 3. Time-course of the conversion of H alkyl–lyso PAF
 . w3 x  . w3 x  .I to H alkyl–PC ‘ , and H alkyl–neutral lipids l by
 6.K562 cells. Cells 5=10 were washed twice to eliminate serum
and were incubated at 378C in 1 ml of RPMI 1640 with labeled
lyso PAF. After various time of incubation lipids in cells and
supernatants were extracted and labeled compounds separated
using TLC plates. Results are expressed as the percentage of total
 .  .radioactivity in dpm recovered in cells upper and supernatants
 .lower . The values are means"SEM of three experiments in
duplicate.
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Table 1
w3 x w3 xConversion of H PAF and H lyso PAF into labeled metabo-
lites by freshly-isolated human bone marrow erythroblasts and
blood erythrocytes
 .Labeled metabolites %
Lyso PAF PAF PC NL
ErythroblastsqPAF 6.3"3 35.0"5 20.2"3 38"11
Erythroblastsqlyso PAF 13.5"3 0 73.7"4 12.8"5
ErythrocytesqPAF 9.8"3 71.5"7 7.1"2 11.5"3
Erythrocytesqlyso PAF 71.2"11 0 13.9"4 14.6"7
 6 . Marrow erythroblasts 2=10 cells and blood erythrocytes 5=
8 .10 cells were incubated for 3 and 5 h, respectively. Results are
expressed as the percentage of total radioactivity recovered in
cells following incubation of cells with labeled PAF and lyso
PAF. Mean"SEM of three independent experiments in dupli-
cate.
As reported in Table 1, freshly-isolated bone mar-
row erythroblasts rapidly metabolized PAF and lyso
PAF into 1-alkyl-analogue of PC. The metabolism of
PAF and lyso PAF by blood erythrocytes was less
potent than by bone marrow erythroblasts.
[3 ]3.3. Effect of PAF on H thymidine incorporation by
K562 cells
FCS stimulated in a dose-dependent manner
w3 xH thymidine incorporation into K562 cells. After
three days of growth in 1, 5 and 20% FCS cells
incorporated 7519"959, 11755"1175 and 15045
"1300 dpm, respectively mean"SEM of 13 exper-
.  .iments . PAF significantly P-0.05 stimulated
w3 xH thymidine incorporation in K562 cells cultured in
 .1% FCS Fig. 4 . In these culture conditions, the
non-metabolizable PAF agonist induced higher ef-
fects than PAF on DNA synthesis. No effect of PAF
 .and C–PAF 10 mM to 10 pM was found on the
w3 xH thymidine incorporation when cells were cultured
 .  .in 5% FCS Fig. 3 . While BN 52021 10 mM had
w3 xno effect on H thymidine incorporation, CV 3988
 .10 mM decreased it by 25%. These two PAF recep-
tor antagonists had no effect between 1 mM and
 .0.1 nM data not shown .
3.4. Detection of PAF receptor mRNA in K562 cells
We used RT–PCR to detect and to characterize
 .PAF receptor mRNA in cultured K562 cells Fig. 5 .
U937 cells were used as positive controls since they
had been previously shown to express PAF receptors
w x17 . As in U937 cells, the PAF receptor mRNA was
detected in cultured K562 cells. In three independent
experiments, the PCR products migrated at position
consistent with the expected size. The cloning of
these products and their sequencing gave a further
confirmation of the presence of PAF receptor mRNA
 .in K562 cells data not shown .
3.5. PAF production by K562 cells
The stimulation of K562 cells with 2 mM calcium
ionophore for 10 min enhanced by 2-fold their PAF
 .  .Fig. 4. Effects of PAF upper and C–PAF lower on
w3 xH thymidine incorporation of K562 cells cultured in 1 and 5%
FCS. Mean"SEM of five experiments. ) P -0.05 as compared
 .to control values t-test for paired data . Mean dpm incorporated
in control cells for PAF experiments were 9543 and 13559 for 1
and 5% FCS, respectively. Mean dpm incorporated in control
cells for C–PAF experiments were 7332 and 11440 for 1 and 5%
FCS, respectively.
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Fig. 5. Ethidium bromide agarose gel of RT–PCR amplification
of PAF receptor mRNA. RNA was extracted from K562 cells and
 .U937 cells positive control and RT–PCR was performed using
primers according to the Section 2. Lanes 1 and 2: K562 cells;
lane 3: resting U937 cells; lane 4: U937 cells stimulated with
 .TNF-a 100Urml for 2 h.
synthesis as compared with controls 1050"152 pg
PAFr5=106 cells vs. 479"70 pg PAFr5=106
.cells, ns3 . Stimulation with calcium ionophore
induced the release of about 1r5 of the produced
PAF into the supernatant, the other part remaining
cell-associated. When control ionophore was ex-
Fig. 6. TLC elution profile of PAF extracted from K562 cells.
Samples were pooled and eluted on a TLC plate as described in
Section 2. Areas of 1 cm length were extracted, suspended in
 .60% ethanol, and assayed for PAF activity B using aggregation
w3 xof washed rabbit platelets. H PAF was used as standard and
 .dpm counts ‘ in areas of 1 cm length were determined using a
liquid scintillation counter.
tracted and assayed in the bioassay, no platelet-aggre-
 .gation was found data not shown . Cells stimulated
in the presence of 100 nM lyso PAF and 100 mM
acetyl-CoA known as the acetate donor molecule for
.the acetylation of lyso PAF into PAF did not pro-
duce more PAF than ionophore-stimulated cells with-
out exogenous addition of precursors data not
.shown . K562 cells contained 18.7"1.3 ng lyso
6 PAFr5=10 cells mean"SEM of five experi-
.ments indicating a molecular ratio of PAF to lyso
PAF in K562 cells of 1:40.
The platelet-aggregating activity was indistinguish-
able from synthetic PAF by the following physico-
 .chemical and biological criteria: a it induced aggre-
gation of washed-rabbit platelets that were refractory
 .to ADP and arachidonic acid; b the platelet aggre-
gation was completely inhibited by the PAF antago-
 .nists BN 52021 and CV 3988 data not shown ; and
 .c during TLC analysis, the platelet-aggregating ac-
tivity was eluted with a retention time similar to that
 .of synthetic PAF Fig. 6 .
4. Discussion
The human K562 erythroid cell line produces PAF.
The platelet-aggregating activity is PAF, as evi-
denced by its TLC behaviour and by the capacity of
PAF receptor antagonists to inhibit it. Similarly, to
w xnumerous cell types 18–21 , the majority of the
synthesized PAF remains cell-associated. Lyso PAF
is present in K562 cells in the absence of stimulation.
When supplemented with synthetic lyso PAF and
acetyl-CoA, ionophore-stimulated cells do not pro-
duce more PAF than without addition suggesting that
K562 cells contain enough acetate donor and lyso
PAF to form PAF. In contrast to erythrocytes which
do not synthesize PAF when stimulated with calcium
w xionophore 5 , K562 cells generate PAF suggesting
that nucleated erythroid precursors of the bone mar-
row might be a putative cell source of the human
w xbone marrow PAF 13,22,23 .
w xAs reported for other cell types 24–27 , K562
cells and bone marrow erythroblasts metabolize PAF
in 1-alkyl–2-acyl analogue of PC. Both cell types
contain an AHA, suggesting that they metabolize
PAF through a deacetylation–reacylation pathway.
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Moreover, K562 cells and bone marrow erythroblasts
w3 xquickly convert exogenous H lyso PAF into 1-al-
kyl–2-acyl analogue of PC indicating that the acyla-
tion process is particularly active in these cells. In
this regard, K562 cells and marrow erythroblasts are
w xsimilar to rabbit endometrial cells 28 , but differ
w x w xfrom rabbit platelets 29 and rat Kupffer cells 30 .
As compared with bone marrow erythroblasts, blood
erythrocytes contain a low AHA and their metabolism
of PAF and lyso PAF is weak. These results are
consistent with studies reporting that blood erythro-
cyte AHA and ATA are gradually reduced during in
w xvivo aging of erythrocytes 6 . The weak metabolism
of PAF and lyso PAF found after several hours of
incubation with blood erythrocytes might be related
to some cell hemolysis resulting in the release of
their intracellular fluid. This mechanism has been
previously suggested to find a role for the human
w xerythrocyte AHA 5 .
The structurally-related PAF receptor antagonist
CV 3988 inhibits PAF metabolism while the struc-
turally-unrelated PAF receptor antagonist BN 52021
is inactive. The effect of CV 3988 may be due to the
w3 xdisplacement of H PAF from membrane PAF recep-
tors thus preventing its metabolism. RT–PCR experi-
ments reveal the presence of PAF receptor mRNA in
K562 cells.
PAF increases thymidine incorporation in K562
cells and a non-metabolizable PAF agonist has a
more potent effect than PAF on thymidine incorpora-
tion. This effect is weak but significant. It is found in
low serum concentrations, a result that might be
related to the facts that K562 cells metabolize PAF
and that FCS contains AHA. The effects of PAF on
K562 growth might be mediated through their mem-
brane PAF receptors. Our results suggest, for the first
time, that PAF might affect human erythropoiesis as
w xpreviously reported for human lymphopoiesis 31,32 .
It is of evidence that further studies are required to
clarify the precise role of PAF on human erythro-
poiesis, i.e, from bone marrow immature progenitors
to mature blood erythrocytes.
In conclusion, the present study reports differences
in the productionrdegradation of PAF from marrow
erythroid precursors to erythrocytes and that the im-
mature erythroid K562 cell line might be an interest-
ing tool for investigating the role of PAF on human
erythropoiesis.
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